ClinicalTrials.gg
Status unknownNCT04815148Updated Mar 24, 2021

MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis

A Phase 1 interventional study of MH004 Ia(0.1%) and MH004 Ia(0.3%) in Atopic Dermatitis and Rheumatoid Arthritis, sponsored by Minghui Pharmaceutical Pty Ltd. Status unknown. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Minghui Pharmaceutical Pty Ltd · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.

Read the detailed description

The study includes 2 parts:The first part (Phase Ia) is a single ascending dose (SAD) study and a multiple ascending dose (MAD) study in healthy volunteers. The second part (Phase Ib) includes two randomised, Placebo-Controlled 28-day repeated dose studies for AD and RA participants respectively, using defined concentrations of the topical cream based on the PK and safety data in healthy volunteers in Phase Ia.

02

Conditions studied

  • Atopic Dermatitis
  • Rheumatoid Arthritis
03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's planned enrollment of 72 is below the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Minghui Pharmaceutical Pty Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase Ia and Ib:

  1. Phase Ia: Adults, age 18 - 45 years old, inclusive, at time of screening. Phase Ib: Adults, age 18 - 70 years old, inclusive, at time of screening.
  2. Willing and able to understand and sign an form and to comply with all aspects of the protocol.
  3. Participants whose (BMI) at screening is within a range of ≥ 18.5 kg/m2 and \<35 kg/m2.

    (BMI = Body Weight (kg) / [Height (m) × Height (m)])

  4. Has abstained from smoking or use of tobacco products from 6 months prior to study drug administration and for the entire duration of the study.
  5. Participant's medical history shows no to JAK inhibitors.
  6. Participants judged to be in good health by the Investigator based upon the results of physical examinations (PEs), 12-lead (ECG) test, and all items of routine laboratory tests, including serum biochemistry, hematology and urinalysis, are within normal range, or if outside normal range they are deemed not as judged by the Investigator. Assessment items of blood biochemistry include albumin, total protein, total , ALP, , SGPT, BUN, serum creatinine, CK and fasting lipid profile (total cholesterol, LDL, HDL and triglycerides). Assessment items of hematology tests include RBC count, WBC with differential counts, , hematocrit and count. Assessment items of urinalysis include pH, colour, appearance, gravity, erythrocyte, leukocyte, glucose, protein, ketones and nitrite.

    For the ECG test, must be ≤450msec for females or males, and PR interval \<120msec and no evidence of bundle branch block.

  7. Willingness of men and women of to observe conventional and highly effective from the beginning of the study screening until 6 months after receiving the last treatment of product. A highly effective method of contraception is defined as follows:

    Highly Effective Methods That Have Low User Dependency

    • Implantable progestogen-only hormone contraception associated with inhibition of ovulation.
    • Intrauterine device (IUD).
    • Intrauterine hormone-releasing system (IUS).
    • Bilateral tubal occlusion.
    • Vasectomized partner (is a highly effective contraceptive method provided that the partner is the sole sexual partner of the and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.

    Highly Effective Methods That Are User Dependent (must be used in combination with a male or female condom)

    • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal, injectable.
    • Progestogen-only hormone contraception associated with inhibition of ovulation: oral, injectable.
  8. WOCBP must have a negative pregnancy test at Screening and Day 1 and be willing to have additional pregnancy tests as required throughout the study.
  9. Males must not donate sperm for at least 90 days after the last dose of study drug.
  10. Participants are a current non-smoker (and has not smoked in the 6 months prior to baseline) and will not smoke throughout the course of the study. Screening cotinine test must be negative.

    Additional Inclusion criteria for Phase Ib (Study 2-1, AD participants):

  11. Participants who are diagnosed with mild to moderate atopic dermatitis for ≥3 months prior to screening based on the Hanifin and Rajka Criteria. Mild to moderate AD is defined as BSA 2-20%; EASI 3-16; IGA 2 - 3 at both the screening and Day 1 visit.
  12. Participants with a Target Area of Atopic Dermatitis of approx. 10 x 10cm on any part of the body other than the scalp, face, palms of hands, soles of feet, buttocks or groin to apply the Study Drug. The Target Lesion Area score needs to be between mild (2) to moderate (3) on the Disease Affected Eczema Area and Severity Indices (EASI) at screening and Day 1.
  13. Participant is able to apply the study drug to the Target Lesion Area; or if the Target Lesion is not easily reached (i.e. on their back), has someone who is willing and able to apply the study drug as prescribed during the treatment period.
  14. Participants who agree to discontinue all treatment used for their AD, such as topical antihistamines, topical antimicrobials, topical or oral , systemic immune modulating agents and light treatments, as well as bleach baths and avoid prolonged sun exposure during the study period for/on the affected site(s) (except the standard medication oral antihistamine levocetirizine and rescue medication prescribed by the study Investigator(s)). Participants who are taking oral antihistamines need to be on a stable dose for at least 2 months.
  15. Participants are required to stop using prohibited topical treatments for at least 14 days before the first investigational drug dose administration (or longer if the treatment half-life requires so 5 half-lives should have elapsed) and prohibited systemic treatment drugs for 28 days before the first investigational drug dose administration (or longer if the treatment half-life requires so 5 half-lives should have elapsed).

    Additional Inclusion criteria for Phase Ib (Study 2-2, RA participants):

  16. Diagnosed with Rheumatoid arthritis (RA) prior to screening who fulfil the 2010 ACR/EULAR classification for RA.
  17. Mild to moderate disease activity at screening (DAS 28-CRP ≤ 4.5 and ≥ 2.6).
  18. Active RA in one Target Joint of either hand or wrist at screening and baseline where both swelling and tenderness/pain is present.

Exclusion criteria

Exclusion Criteria:

Phase Ia and Ib:

  1. Participants with conditions at the study drug application site(s) that would interfere with the study drug administration, skin assessment, or reaction to study drug.

    For example: presence of open sores; obvious differences in skin color between applications sites/discolouration such as vitiligo; excessive hair; scar tissue; tattoo.

  2. Participants with any unstable health status, defined as having newly diagnosed medical conditions or symptoms of a medical condition that is not yet diagnosed within 30 days prior to the first dose of the study drug.
  3. Healthy participants and RA participants only (i.e. does not apply to AD participants): Participants with any diagnosed dermatological condition within 180 days prior to the first study dose.
  4. History of anaphylaxis.
  5. Participants with any (as judged by the Investigator) hematological, endocrine, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorder.
  6. Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral .
  7. Participants with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of the study medication.

    This includes a screening \<60mL/min/1.73m2 or screening transaminases > 1.5 x .

  8. Participant had participated in any drug trial and took any investigational drug within 60 days prior to the first study dose.
  9. Participant had blood donation of more than 250 mL within 60 days or 500 mL within 90 days prior to the first study drug dose.
  10. Participant has current drug abuse or alcohol abuse per Investigator judgement. Participants must have a negative drug and alcohol test at screening and day 1.
  11. Participants who are inappropriate to participate in this study, as judged by the Investigator.
  12. Participants with any history of or current unstable mental health condition or any lifetime history of suicidal behaviour, as per Investigator judgement.
  13. Participants who have known to the study medication.
  14. Participants who are pregnant or breast-feeding or intend to become pregnant during the course of the treatment and follow-up periods.
  15. Any history of of any organ system (other than cervical carcinoma in situ or non-melanoma skin cancers that have been excised) within 5 years prior to study entry.
  16. Major surgery (including joint surgery) within 8 weeks prior to screening or during the course of the study.
  17. Known active current, or recent history within 3 months, requiring treatment of bacterial, viral, fungal, mycobacterial or other infections.
  18. Vaccinated or exposed to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or is expected to be vaccinated or to have household exposure to these vaccines during treatment or up until the follow-up visit.
  19. A history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
  20. Any history of any blood clots or clotting disorders (e.g. Deep Vein Thrombosis, Pulmonary Embolism, coagulopathy).
  21. Any known immunodeficiency disorder.
  22. Mycobacterium tuberculosis (TB) infection as follows:

    • A positive QuantiFERON TB test within the 12 weeks prior to screening or during screening.
    • Any chest imaging (e.g. x-ray, CT) taken at screening or within the 12 weeks prior to screening with changes suggestive of active TB.
    • Been treated or is currently being treated for active or latent TB infection.
    • A history of either untreated or inadequately treated latent or active TB infection.

    Participants with an indeterminate QuantiFERON TB test can have the test repeated and if a negative result is obtained, enrollment may proceed. If the repeat is indeterminate again, the participant will be excluded.

  23. Participants who have been tested positive for the following tests:

    • (HIV)
    • virus (HBV): HBsAg or anti-HBc
    • virus (HCV)

    Additional exclusion criteria for Phase Ib (Study 2-1, AD participants):

  24. Participants with active forms of dermatological conditions such as contact dermatitis, seborrheic, discoid, gravitational, asteatotic and dyshidrotic eczema) or other inflammatory skin diseases that are not AD, such as psoriasis, viral infection, fungal infection or bacterial infection.
  25. Participants who are inevitable to engage in activities involving excessive or prolonged exposure to sunlight.
  26. Treatment with a biologic agent or JAK inhibitor at any time prior to baseline.

    Additional exclusion criteria Phase Ib (Study 2-2, RA participants):

  27. Rheumatic disease other than rheumatoid arthritis.
  28. Functional class IV American College of Rheumatology (ACR) Classification.
  29. Prior history of or current inflammatory joint disease other than rheumatoid arthritis (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondylarthritis, reactive arthritis, overlap connective tissue disease). History of secondary Sjogren's syndrome is permitted.
  30. Treatment with a biologic agent or JAK inhibitor at any time prior to baseline.

    Note:

    Treatment with traditional DMARDs is allowed provided that the dose is stable for ≥3 months prior to baseline.

    Oral corticosteroids (e.g. Prednisolone) are allowed if the dose is ≤10mg per day and has been stable for two weeks prior to baseline.

    NSAIDs and other low-potency analgesics are allowed if the dose has been stable for two weeks prior to baseline. High potency analgesics are excluded.

  31. Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline.
  32. Previous treatment with tocilizumab.
  33. History of or currently active primary or secondary immunodeficiency.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Phase Ia: MH004 (0.1%) in healthy volunteers

    SAD and MAD

    Drug: MH004 Ia(0.1%)

  • Experimental
    Phase Ia: MH004 (0.3%) in healthy volunteers

    SAD and MAD

    Drug: MH004 Ia(0.3%)

  • Experimental
    Phase Ia: MH004 (1%) in healthy volunteers

    SAD and MAD

    Drug: MH004 Ia(1%)

  • Experimental
    Phase Ia: MH004 (3%) in healthy volunteers

    SAD and MAD

    Drug: MH004 Ia(3%)

  • Experimental
    Phase Ib-1: MH004 (0.1%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 Ib-1(0.1%)

  • Experimental
    Phase Ib-1: MH004 (0.3%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 Ib-1(0.3%)

  • Experimental
    Phase Ib-1: MH004 (1%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 Ib-1(1%)

  • Experimental
    Phase Ib-2: MH004 (0.3%) in Rheumatoid Arthritis

    28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis

    Drug: MH004 Ib-2(0.3%)

  • Experimental
    Phase Ib-2: MH004 (1%) in Rheumatoid Arthritis

    28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis

    Drug: MH004 Ib-2(1%)

  • Experimental
    Phase Ib-2: MH004 (3%) in Rheumatoid Arthritis

    28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis

    Drug: MH004 Ib-2(3%)

Interventions

  • Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

    Also known as: MH004 Topical Cream

  • Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

    Also known as: MH004 Topical Cream

  • Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

    Also known as: MH004 Topical Cream

  • Spread approx. 1 g of MH004 topical cream to the upper thigh skin.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

    Also known as: MH004 Topical Cream

  • Spread approx. 0.5 g of MH004 topical cream to the Target Joint.

    Also known as: MH004 Topical Cream

06

What researchers measure

Primary outcomes

  1. To evaluate the incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].

    Assess incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0 The incidence, nature, and severity of AEs/SAEs including relationship to study treatment from MAD initial study drug administration time of randomisation until Day 14 for MAD participants. The incidence, nature, and severity of AEs/SAEs leading to treatment discontinuation from MAD initial study drug administration time of randomisation until Day 7 for MAD participants. Clinically significant changes in laboratory parameters, vital signs, 12-lead ECG, and other safety assessments from initial study drug administration time of randomisation until Day 7 for SAD participants. Clinically significant changes in laboratory parameters, vital signs, 12-lead ECG, and other safety assessments from MAD initial study drug administration time of randomisation until Day 14 for MAD participants.

    Time frame: 1 year

  2. To determine the maximum tolerated dose (MTD) of MH004 topical cream.

    The determination of the maximum tolerated dose for phase 2.

    Time frame: 1 year

  3. To establish the recommended phase 2 dose (RP2D).

    The determination of RP2D for phase 2 according to the result of dose expansion

    Time frame: 1 year

Secondary outcomes

  1. Characterization of Pharmacokinetics (Cmax)

    Maximum drug concentration (Cmax)

    Time frame: Up to 6 Months

  2. Characterization of Pharmacokinetics (AUC)

    Area Under the Curve (AUC)

    Time frame: Up to 6 Months

  3. Characterization of Pharmacokinetics (CL)

    Clearance (CL)

    Time frame: Up to 6 Months

  4. Characterization of Pharmacokinetics (t1/2)

    Elimination half-life (t1/2)

    Time frame: Up to 6 Months

  5. Change from baseline Target Lesion EASI score

    Percentage of Participants Achieving EASI50,EASI75,EASI90 from Baseline. The EASI50 is defined as a ≥ 50% improvement from baseline in EASI score. The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: 1 year

  6. Change from baseline Target Joint swelling and tenderness score

    Change from baseline Target Joint swelling and tenderness score by visual anabg scale(VAS)on Day7, Day14 and Day 28 in participants with mild to moderaterheumatoid arthritis.The VAS score runs from 0 to 10, with higher scores indicating worse outcome

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2021; primary completion for Mar 2022, 11 months later.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 11 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 24, 2021
StartEst.
Apr 1, 2021
Primary completionEst.
Mar 31, 2022
CompletionEst.
Mar 31, 2022
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04815148
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Apr 1, 2021 (estimated)
Primary completion
Mar 31, 2022 (estimated)
Completion
Mar 31, 2022 (estimated)
Last update
Mar 24, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MH004

Start the discussion